MYCN and neoplasm: UKCCSG-SIOP-PNET3 biological studies first identified the WNT subgroup and its favourable prognosis [32,57] and subsequently developed integrated schemes for the stratification of patients into three risk-groups using combined clinical, pathological and molecular factors: favourable-risk (WNT subgroup), high-risk (non-WNT tumours with M+, R+, LCA pathology or MYC/MYCN amplification) and standard-risk (all remaining patients) [3].